Meeker Daniella, Linder Jeffrey A, Fox Craig R, Friedberg Mark W, Persell Stephen D, Goldstein Noah J, Knight Tara K, Hay Joel W, Doctor Jason N
Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles2RAND Corporation, Santa Monica, California.
Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, Massachusetts4Harvard Medical School, Boston, Massachusetts.
JAMA. 2016 Feb 9;315(6):562-70. doi: 10.1001/jama.2016.0275.
Interventions based on behavioral science might reduce inappropriate antibiotic prescribing.
To assess effects of behavioral interventions and rates of inappropriate (not guideline-concordant) antibiotic prescribing during ambulatory visits for acute respiratory tract infections.
DESIGN, SETTING, AND PARTICIPANTS: Cluster randomized clinical trial conducted among 47 primary care practices in Boston and Los Angeles. Participants were 248 enrolled clinicians randomized to receive 0, 1, 2, or 3 interventions for 18 months. All clinicians received education on antibiotic prescribing guidelines on enrollment. Interventions began between November 1, 2011, and October 1, 2012. Follow-up for the latest-starting sites ended on April 1, 2014. Adult patients with comorbidities and concomitant infections were excluded.
Three behavioral interventions, implemented alone or in combination: suggested alternatives presented electronic order sets suggesting nonantibiotic treatments; accountable justification prompted clinicians to enter free-text justifications for prescribing antibiotics into patients' electronic health records; peer comparison sent emails to clinicians that compared their antibiotic prescribing rates with those of "top performers" (those with the lowest inappropriate prescribing rates).
Antibiotic prescribing rates for visits with antibiotic-inappropriate diagnoses (nonspecific upper respiratory tract infections, acute bronchitis, and influenza) from 18 months preintervention to 18 months afterward, adjusting each intervention's effects for co-occurring interventions and preintervention trends, with random effects for practices and clinicians.
There were 14,753 visits (mean patient age, 47 years; 69% women) for antibiotic-inappropriate acute respiratory tract infections during the baseline period and 16,959 visits (mean patient age, 48 years; 67% women) during the intervention period. Mean antibiotic prescribing rates decreased from 24.1% at intervention start to 13.1% at intervention month 18 (absolute difference, -11.0%) for control practices; from 22.1% to 6.1% (absolute difference, -16.0%) for suggested alternatives (difference in differences, -5.0% [95% CI, -7.8% to 0.1%]; P = .66 for differences in trajectories); from 23.2% to 5.2% (absolute difference, -18.1%) for accountable justification (difference in differences, -7.0% [95% CI, -9.1% to -2.9%]; P < .001); and from 19.9% to 3.7% (absolute difference, -16.3%) for peer comparison (difference in differences, -5.2% [95% CI, -6.9% to -1.6%]; P < .001). There were no statistically significant interactions (neither synergy nor interference) between interventions.
Among primary care practices, the use of accountable justification and peer comparison as behavioral interventions resulted in lower rates of inappropriate antibiotic prescribing for acute respiratory tract infections.
clinicaltrials.gov Identifier: NCT01454947.
基于行为科学的干预措施可能会减少不恰当的抗生素处方。
评估行为干预措施以及在急性呼吸道感染门诊就诊期间不恰当(不符合指南)抗生素处方的发生率。
设计、地点和参与者:在波士顿和洛杉矶的47家初级保健机构中进行的整群随机临床试验。参与者为248名登记的临床医生,随机分为接受0、1、2或3种干预措施,为期18个月。所有临床医生在登记时均接受了抗生素处方指南的教育。干预措施于2011年11月1日至2012年10月1日期间开始。最新开始的机构的随访于2014年4月1日结束。排除患有合并症和并发感染的成年患者。
三种行为干预措施,单独或联合实施:建议替代方案,在电子医嘱集中给出非抗生素治疗建议;责任说明提示临床医生在患者的电子健康记录中输入使用抗生素的自由文本说明;同行比较,向临床医生发送电子邮件,将他们的抗生素处方率与“表现最佳者”(不恰当处方率最低者)的进行比较。
从干预前18个月到干预后18个月,针对抗生素使用不恰当诊断(非特异性上呼吸道感染、急性支气管炎和流感)的就诊的抗生素处方率,对每种干预措施的效果进行调整以考虑同时存在的干预措施和干预前趋势,并对机构和临床医生采用随机效应。
在基线期有14753次针对抗生素使用不恰当的急性呼吸道感染的就诊(患者平均年龄47岁;69%为女性),在干预期有16959次就诊(患者平均年龄48岁;67%为女性)。对照机构的平均抗生素处方率从干预开始时的24.1%降至干预第18个月时的13.1%(绝对差异为-11.0%);建议替代方案组从22.1%降至6.1%(绝对差异为-16.0%)(差异差值为-5.0% [95%CI,-7.8%至0.1%];轨迹差异P = 0.66);责任说明组从23.2%降至5.2%(绝对差异为-18.1%)(差异差值为-7.0% [95%CI,-9.1%至-2.9%];P < 0.001);同行比较组从19.9%降至3.7%(绝对差异为-16.3%)(差异差值为-5.